URMC / Research / Clinical Trials / Study Details UGUB20041, Fung, HCRN GU18-343, Urinary Bladder Neoplasms, Cabozantinib, AtezolizumabResearch Question:Assessing the activity of cabozantinib combined with atezolizumab in patients with resectable muscle-invasive urothelial carcinoma who are ineligible for cisplatin-based therapy or decline cisplatin-based therapy. Basic Study Information Purpose:This is an open-label phase II study assessing the activity of cabozantinib combined with atezolizumab in patients with resectable muscle-invasive urothelial carcinoma who are ineligible for cisplatin-based therapy or decline cisplatin-based therapy. Each cycle equals 21 days. The dose of atezolizumab is 1200 mg IV flat dose every 3 weeks (Day 1) plus cabozantinib 40 mg orally daily (Day 1 through Day 21). Patients will receive three cycles of treatment prior to cystectomy unless they discontinue treatment for unacceptable toxicity or progressive disease by RECIST v1.1 or withdraw consent. Location: University of Rochester Medical CenterStudy Reference #: UGUB20041Lead Researcher (Principal Investigator) Lead Researcher: Deepak Sahasrabudhe, MD Study Contact InformationStudy Coordinator: Tina BowdishPhone: +1 585-275-9475Email: tina_bowdish@urmc.rochester.edu Additional Study Details URMC / Wilmot Cancer Institute /Research / Clinical Trials / Study Details Trial Not Found The study you are looking for is not active at this time. Return to Search